Update on Hsp90 inhibitors in clinical trial

Current Topics in Medicinal Chemistry

Volumn 9, Issue 15, 2009, Pages 1479-1492

  Kim, Y S ^a   Alarcon, S V ^a   Lee, S ^a   Lee, M J ^a   Giaccone, G ^a   Neckers, L ^a   Trepel, J B ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Clinical trial; Hsp90 inhibitors; Targeted therapy

Indexed keywords

17 DEMETHOXY 17 (2 DIMETHYLAMINOETHYLAMINO)GELDANAMYCIN; 6 CHLORO 9 [(4 METHOXY 3,5 DIMETHYLPYRIDIN 2 YL)METHYL] 9H PURIN 2 AMINE; ABI 010; ALVESPIMYCIN; AMINO ACETIC ACID 4 [2 CARBAMOYL 5 (6,6 DIMETHYL 4 OXO 3 TRIFLUOROMETHYL 4,5,6,7 TETRAHYDROINDAZOL 1 YL)PHENYLAMINO]CYCLOHEXYL ESTER METHANESULFONATE; AT 13387; AUY 922; BIIB 021; BIIB 028; BORTEZOMIB; CNF 1010; CNF 2024; CYTARABINE; DOCETAXEL; GELDANAMYCIN; GEMCITABINE; HEAT SHOCK PROTEIN 90 INHIBITOR; HSP 990; IMATINIB; IPI 493; IRINOTECAN; KOS 1022; KW 2478; MPC 3100; PACLITAXEL; RITUXIMAB; SNX 5422; SORAFENIB; STA 9090; TANESPIMYCIN; TANESPIMYCIN HYDROQUINONE; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; XL 888;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; B CELL LYMPHOMA; BLOOD DISEASE; BREAST CANCER; CARCINOMA; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DRUG DOSE ESCALATION; DRUG INHIBITION; DRUG MECHANISM; DRUG MEGADOSE; DRUG TARGETING; GASTROINTESTINAL STROMAL TUMOR; HODGKIN DISEASE; HUMAN; KIDNEY CARCINOMA; KIDNEY TUMOR; LARGE CELL LYMPHOMA; LUNG NON SMALL CELL CANCER; LYMPHOMA; MASTOCYTOSIS; MELANOMA; METASTASIS; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; MYELOID LEUKEMIA; MYELOPROLIFERATIVE DISORDER; NEOPLASM; NONHODGKIN LYMPHOMA; ONCOLOGY; OVARY CANCER; PANCREAS ADENOCARCINOMA; PHARMACODYNAMICS; PROSTATE CANCER; REVIEW; SARCOMA; SOLID TUMOR; VON HIPPEL LINDAU DISEASE;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; HSP90 HEAT-SHOCK PROTEINS; HUMANS; NEOPLASMS;

EID: 74249085361     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802609789895728     Document Type: Review

References (86)

1. Uehara, Y. Natural product origins of Hsp90 inhibitors. Curr. Cancer Drug Targets, 2003, 3, 325-330.
2. Uehara, Y.; Hori, M.; Takeuchi, T.; Umezawa, H. Phenotypic change from transformed to normal induced by benzoquinonoid ansamycins accompanies inactivation of p60src in rat kidney cells infected with Rous sarcoma virus. Mol. Cell. Biol., 1986, 6, 2198-2206.
3. Whitesell, L.; Mimnaugh, E.G.; De Costa, B.; Myers, C.E.; Neckers, L.M. Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. Proc. Natl. Acad. Sci. USA, 1994, 91, 8324-8328.
4. Banerji, U. Heat shock protein 90 as a drug target: some like it hot. Clin. Cancer Res., 2009, 15, 9-14.
5. Erlichman, C. Tanespimycin: the opportunities and challenges of targeting heat shock protein 90. Expert Opin. Investig. Drugs, 2009, 18, 861-868.
6. Mitsiades, C.S.; Hideshima, T.; Chauhan, D.; McMillin, D.W.; Klippel, S.; Laubach, J.P.; Munshi, N.C.; Anderson, K.C.; Richardson, P.G. Emerging treatments for multiple myeloma: beyond immunomodulatory drugs and bortezomib. Semin. Hematol., 2009, 46, 166-175.
7. Taldone, T.; Gozman, A.; Maharaj, R.; Chiosis, G. Targeting Hsp90: small-molecule inhibitors and their clinical development. Curr. Opin. Pharmacol., 2008, 8, 370-374.
8. Richardson, P.G.; Chanan-Khan, A.; Lonial, S.; Krishman, A.; Carroll, M.; Cropp, G.F.; Kersey, K.; Abitar, M.; Johnson, R.G.; Hannah, A.L.; Anderson, K.C. Tanespimycin (T) + Bortezomib (BZ) in Multiple Myeloma (MM): Confirmation of the recommended dose using a novel formulation [abstract]. ASH Annu. Meet. Abstr., 2007, 110, 1165.
9. Solit, D.B.; Ivy, S.P.; Kopil, C.; Sikorski, R.; Morris, M.J.; Slovin, S.F.; Kelly, W.K.; DeLaCruz, A.; Curley, T.; Heller, G.; Larson, S.; Schwartz, L.; Egorin, M.J.; Rosen, N.; Scher, H.I. Phase I trial of 17-allylamino-17- demethoxygeldanamycin in patients with advanced cancer. Clin. Cancer Res., 2007, 13, 1775-1782.
10. Grem, J.L.; Morrison, G.; Guo, X.D.; Agnew, E.; Takimoto, C.H.; Thomas, R.; Szabo, E.; Grochow, L.; Grollman, F.; Hamilton, J.M.; Neckers, L.; Wilson, R.H. Phase I and pharmacologic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with solid tumors. J. Clin. Oncol., 2005, 23, 1885-1893.
11. Ramanathan, R.K.; Egorin, M.J.; Eiseman, J.L.; Ramalingam, S.; Friedland, D.; Agarwala, S.S.; Ivy, S.P.; Potter, D.M.; Chatta, G.; Zuhowski, E.G.; Stoller, R.G.; Naret, C.; Guo, J.; Belani, C.P. Phase I and pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with refractory advanced cancers. Clin. Cancer Res., 2007, 13, 1769-1774.
12. Nowakowski, G.S.; McCollum, A.K.; Ames, M.M.; Mandrekar, S.J.; Reid, J.M.; Adjei, A.A.; Toft, D.O.; Safgren, S.L.; Erlichman, C. A phase I trial of twice-weekly 17-allylamino-demethoxygeldanamycin in patients with advanced cancer. Clin. Cancer Res., 2006, 12, 6087-6093.
13. Banerji, U.; O'Donnell, A.; Scurr, M.; Pacey, S.; Stapleton, S.; Asad, Y.; Simmons, L.; Maloney, A.; Raynaud, F.; Campbell, M.; Walton, M.; Lakhani, S.; Kaye, S.; Workman, P.; Judson, I. Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies. J. Clin. Oncol., 2005, 23, 4152-4161.
14. Goetz, M.P.; Toft, D.; Reid, J.; Ames, M.; Stensgard, B.; Safgren, S.; Adjei, A.A.; Sloan, J.; Atherton, P.; Vasile, V.; Salazaar, S.; Adjei, A.; Croghan, G.; Erlichman, C. Phase I trial of 17-allylamino-17- demethoxygeldanamycin in patients with advanced cancer. J. Clin. Oncol., 2005, 23, 1078-1087.
15. Ramanathan, R.K.; Trump, D.L.; Eiseman, J.L.; Belani, C.P.; Agarwala, S.S.; Zuhowski, E.G.; Lan, J.; Potter, D.M.; Ivy, S.P.; Ramalingam, S.; Brufsky, A.M.; Wong, M.K.; Tutchko, S.; Egorin, M.J. Phase I pharmacokinetic- pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin (17AAG, NSC 330507), a novel inhibitor of heat shock protein. 90,. in patients with refractory advanced cancers. Clin. Cancer Res., 2005, 11, 3385-3391.
16. Chiosis, G.; Neckers, L. Tumor selectivity of Hsp90 inhibitors: the explanation remains elusive. ACS Chem. Biol., 2006, 1, 279-284.
17. Bagatell, R.; Gore, L.; Egorin, M.J.; Ho, R.; Heller, G.; Boucher, N.; Zuhowski, E.G.; Whitlock, J.A.; Hunger, S.P.; Narendran, A.; Katzenstein, H.M.; Arceci, R.J.; Boklan, J.; Herzog, C.E.; Whitesell, L.; Ivy, S.P.; Trippett, T.M. Phase I pharmacokinetic and pharmacodynamic study of 17-N-allylamino-17- demethoxygeldanamycin in pediatric patients with recurrent or refractory solid tumors: a pediatric oncology experimental therapeutics investigators consortium study. Clin. Cancer Res., 2007, 13, 1783-1788.
18. Weigel, B.J.; Blaney, S.M.; Reid, J.M.; Safgren, S.L.; Bagatell, R.; Kersey, J.; Neglia, J.P.; Ivy, S.P.; Ingle, A.M.; Whitesell, L.; Gilbertson, R.J.; Krailo, M.; Ames, M.; Adamson, P.C. A phase I study of 17-allylaminogeldanamycin in relapsed/refractory pediatric patients with solid tumors: a Children's Oncology Group study. Clin. Cancer Res., 2007, 13, 1789-1793.
19. Williams, R. Discontinued drugs in 2008: oncology drugs. Expert Opin. Investig. Drugs, 2009.
20. Ronnen, E.A.; Kondagunta, G.V.; Ishill, N.; Sweeney, S.M.; Deluca, J.K.; Schwartz, L.; Bacik, J.; Motzer, R.J. A phase II trial of 17-(Allylamino)-17- demethoxygeldanamycin in patients with papillary and clear cell renal cell carcinoma. Invest. New Drugs, 2006, 24, 543-546.
21. Solit, D.B.; Osman, I.; Polsky, D.; Panageas, K.S.; Daud, A.; Goydos, J.S.; Teitcher, J.; Wolchok, J.D.; Germino, F.J.; Krown, S.E.; Coit, D.; Rosen, N.; Chapman, P.B. Phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with metastatic melanoma. Clin. Cancer Res., 2008, 14, 8302-8307.
22. Heath, E.I.; Hillman, D.W.; Vaishampayan, U.; Sheng, S.; Sarkar, F.; Harper, F.; Gaskins, M.; Pitot, H.C.; Tan, W.; Ivy, S.P.; Pili, R.; Carducci, M.A.; Erlichman, C.; Liu, G. A phase II trial of 17-allylamino-17- demethoxygeldanamycin in patients with hormonerefractory metastatic prostate cancer. Clin. Cancer Res., 2008, 14, 7940-7946.
23. Sausville, E.A. Combining cytotoxics and 17-allylamino, 17-demethoxygeldanamycin: sequence and tumor biology matters. Commentary re: P. Munster et al., Modulation of Hsp90 function by ansamycins sensitizes breast cancer cells to chemotherapy-induced apoptosis in an RB- and schedule-dependent manner. Clin. Cancer Res., 7: 2228-2236, 2001. Clin. Cancer Res., 2001, 7, 2155-2158.
24. Nguyen, D.M.; Lorang, D.; Chen, G.A.; Stewart, J.H.t.; Tabibi, E.; Schrump, D.S. Enhancement of paclitaxel-mediated cytotoxicity in lung cancer cells by 17-allylamino geldanamycin: in vitro and in vivo analysis. Ann. Thorac. Surg., 2001, 72, 371-378; discussion 378-379.
25. Ramalingam, S.S.; Egorin, M.J.; Ramanathan, R.K.; Remick, S.C.; Sikorski, R.P.; Lagattuta, T.F.; Chatta, G.S.; Friedland, D.M.; Stoller, R.G.; Potter, D.M.; Ivy, S.P.; Belani, C.P. A phase I study of 17-allylamino-17- demethoxygeldanamycin combined with paclitaxel in patients with advanced solid malignancies. Clin. Cancer Res., 2008, 14, 3456-3461.
26. Arlander, S.J.; Eapen, A.K.; Vroman, B.T.; McDonald, R.J.; Toft, D.O.; Karnitz, L.M. Hsp90 inhibition depletes Chk1 and sensitizes tumor cells to replication stress. J. Biol. Chem., 2003, 278, 52572-52577.
27. Tse, A.N.; Sheikh, T.N.; Alan, H.; Chou, T.C.; Schwartz, G.K. 90-kDa heat shock protein inhibition abrogates the topoisomerase I poison-induced G2/M checkpoint in p53-null tumor cells by depleting Chk1 and Wee1. Mol. Pharmacol., 2009, 75, 124-133.
28. Tse, A.N.; Klimstra, D.S.; Gonen, M.; Shah, M.; Sheikh, T.; Sikorski, R.; Carvajal, R.; Mui, J.; Tipian, C.; O'Reilly, E.; Chung, K.; Maki, R.; Lefkowitz, R.; Brown, K.; Manova-Todorova, K.; Wu, N.; Egorin, M.J.; Kelsen, D.; Schwartz, G.K. A phase 1 dose-escalation study of irinotecan in combination with 17-allylamino-17-demethoxygeldanamycin in patients with solid tumors. Clin. Cancer Res., 2008, 14, 6704-6711.
29. Modi, S.; Stopeck, A.T.; Gordon, M.S.; Mendelson, D.; Solit, D.B.; Bagatell, R.; Ma, W.; Wheler, J.; Rosen, N.; Norton, L.; Cropp, G.F.; Johnson, R.G.; Hannah, A.L.; Hudis, C.A. Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study. J. Clin. Oncol., 2007, 25, 5410-5417.
30. Modi, S.; Sugarman, S.; Stopeck, A.; Linden, H.; Ma, W.; Kersey, K.; Johnson, R.G.; Rosen; Hannah, A.L.; Hudis, C.A. Phase II trial of the Hsp90 inhibitor tanespimycin (Tan) + trastuzumab (T) in patients (pts) with HER2-positive metastatic breast cancer (MBC) [abstract]. J. Clin. Oncol., 2008, 26, 1027.
31. Richardson, P.G.; Chanan-Khan, A.; Lonial, S.; Krishnan, A.; Carroll, M.; Alsina, M.; Albitar, M.; Berman, D.; Kaplita, S.; Anderson, K. Tanespimycin plus bortezomib in patients with relapsed and refractory multiple myeloma: Final results of a phase I/II study [abstract]. J. Clin. Oncol., 2009, 27, 8503.
32. Riely, G.J.; Stoller, R.; Egorin, M.; Solit, D.; Dunbar, J.; Savage, A.; Walker, J.; Grayzel, D.; Ross, R.; Weiss, G.J. A phase Ib trial of IPI-504 (retaspimycin hydrochloride), a novel Hsp90 inhibitor, in combination with docetaxel [abstract]. J. Clin. Oncol., 2009, 27, 3547.
33. Sequist, L.V.; Gettinger, S.; Natale, R.; Martins, R.; Lilenbaum, R.; Jänne, P.; Gray, J.; Samuel, T.A.; Grayzel, D.; Lynch, T.J. A phase II trial of IPI-504 (retaspimycin hydrochloride), a novel Hsp90 inhibitor, in patients with relapsed and/or refractory stage IIIb or stage IV non-small cell lung cancer (NSCLC) stratified by EGFR mutation status [abstract]. J. Clin. Oncol., 2009, 27, 8073.
34. Oh, W.K.; Stadler, W.M.; Srinivas, S.; Chu, F.; Bubley, G.; Quigley, M.; Goddard, J.; Dunbar, J.; Grayzel, D.; Ross, R.W. A single arm phase II trial of IPI-504 in patients with castration resistant prostate cancer (CRPC) [abstract]. Genitourinary Cancers Symp. Abstr., 2009, 219.
35. Yano, A.; Tsutsumi, S.; Soga, S.; Lee, M.J.; Trepel, J.; Osada, H.; Neckers, L. Inhibition of Hsp90 activates osteoclast c-Src signaling and promotes growth of prostate carcinoma cells in bone. Proc. Natl. Acad. Sci. USA, 2008, 105, 15541-15546.
36. Wagner, A.J.; Morgan, J.A.; Chugh, R.; Rosen, L.S.; George, S.; Gordon, M.S.; Devine, C.M.; Van den Abbeele, A.D.; Grayzel, D.; Demetri, G.D. Inhibition of heat shock protein 90 (Hsp90) with the novel agent IPI-504 in metastatic GIST following failure of tyrosine kinase inhibitors (TKIs) or other sarcomas: Clinical results from phase I trial [abstract]. J. Clin. Oncol., 2008, 26, 10503.
37. Lancet, J.; Baer, M.R.; Gojo, I.; Burton, M.; Quinn, M.; Tighe, S.M.; Bhalla, K.; Kersey, K.; Wells, S.; Zhong, Z.; Sadler, B.; Albitar, M.; Johnson, R.; Hannah, A. Phase I, pharmacokinetic (PK) and pharmacodynamic (PD) study of intravenous alvespimycin (KOS-1022) in patients with refractory hematological malignancies [abstract]. ASH Annu. Meet. Abstr., 2006, 108, 1961.
38. Chiosis, G.; Caldas Lopes, E.; Solit, D. Heat shock protein-90 inhibitors: a chronicle from geldanamycin to today's agents. Curr. Opin. Investig. Drugs, 2006, 7, 534-541.
39. Chiosis, G.; Kang, Y.; Sun, W. Discovery and development of purine-scaffold Hsp90 inhibitors. Expert Opin. Drug Discov., 2008, 3, 99-114.
40. McDonald, E.; Jones, K.; Brough, P.A.; Drysdale, M.J.; Workman, P. Discovery and development of pyrazole-scaffold Hsp90 inhibitors. Curr. Top. Med. Chem., 2006, 6, 1193-1203.
41. Zou, J.; Guo, Y.; Guettouche, T.; Smith, D.F.; Voellmy, R. Repression of heat shock transcription factor HSF1 activation by HSP90 (HSP90 complex) that forms a stress-sensitive complex with HSF1. Cell, 1998, 94, 471-480.
42. Jimeno, A.; Rudek, M.A.; Kulesza, P.; Ma, W.W.; Wheelhouse, J.; Howard, A.; Khan, Y.; Zhao, M.; Jacene, H.; Messersmith, W.A.; Laheru, D.; Donehower, R.C.; Garrett-Mayer, E.; Baker, S.D.; Hidalgo, M. Pharmacodynamic-guided modified continuous reassessment method-based, dose-finding study of rapamycin in adult patients with solid tumors. J. Clin. Oncol., 2008, 26, 4172-4179.
43. Ma, W.W.; Jacene, H.; Song, D.; Vilardell, F.; Messersmith, W.A.; Laheru, D.; Wahl, R.; Endres, C.; Jimeno, A.; Pomper, M.G.; Hidalgo, M. [18F]fluorodeoxyglucose positron emission tomography correlates with Akt pathway activity but is not predictive of clinical outcome during mTOR inhibitor therapy. J. Clin. Oncol., 2009, 27, 2697-2704.
44. Demetri, G.D.; George, S.; Morgan, J.A.; Wagner, A.J.; Quigley, M.T.; Polson, K.; Pokela, J.; Van den Abbeele, A.D.; Adams, J.; Grayzel, D. Inhibition of the Heat Shock Protein 90 (Hsp90) chaperone with the novel agent IPI-504 to overcome resistance to tyrosine kinase inhibitors (TKIs) in metastatic GIST: Updated results of a phase I trial [abstract]. J. Clin. Oncol., 2007, 25, 10024.
45. Smith-Jones, P.M.; Solit, D.; Afroze, F.; Rosen, N.; Larson, S.M. Early tumor response to Hsp90 therapy using HER2 PET: comparison with 18F-FDG PET. J. Nucl. Med., 2006, 47, 793-796.
46. Eiseman, J.L.; Guo, J.; Ramanathan, R.K.; Belani, C.P.; Solit, D.B.; Scher, H.I.; Ivy, S.P.; Zuhowski, E.G.; Egorin, M.J. Evaluation of plasma insulin-like growth factor binding protein 2 and Her-2 extracellular domain as biomarkers for 17-allylamino-17-demethoxygeldanamycin treatment of adult patients with advanced solid tumors. Clin. Cancer Res., 2007, 13, 2121-2127.
47. Elfiky, A.; Saif, M.W.; Beeram, M.; O' Brien, S.; Lammanna, N.; Castro, J.E.; Woodworth, J.; Perea, R.; Storgard, C.; Von Hoff, D.D. BIIB021, an oral, synthetic non-ansamycin Hsp90 inhibitor: Phase I experience. J. Clin. Oncol., 2008, 26, 2503.
48. Montagut, C.; Sharma, S.V.; Shioda, T.; McDermott, U.; Ulman, M.; Ulkus, L.E.; Dias-Santagata, D.; Stubbs, H.; Lee, D.Y.; Singh, A.; Drew, L.; Haber, D.A.; Settleman, J. Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma. Cancer Res., 2008, 68, 4853-4861.
49. Pashtan, I.; Tsutsumi, S.; Wang, S.; Xu, W.; Neckers, L. Targeting Hsp90 prevents escape of breast cancer cells from tyrosine kinase inhibition. Cell Cycle, 2008, 7, 2936-2941.
50. Wang, S.; Pashtan, I.; Tsutsumi, S.; Xu, W.; Neckers, L. Cancer cells harboring MET gene amplification activate alternative signaling pathways to escape MET inhibition but remain sensitive to Hsp90 inhibitors. Cell Cycle, 2009, 8, 2050-2056.
51. Sawai, A.; Chandarlapaty, S.; Greulich, H.; Gonen, M.; Ye, Q.; Arteaga, C.L.; Sellers, W.; Rosen, N.; Solit, D.B. Inhibition of Hsp90 down-regulates mutant epidermal growth factor receptor (EGFR) expression and sensitizes EGFR mutant tumors to paclitaxel. Cancer Res., 2008, 68, 589-596.
52. Xu, W.; Soga, S.; Beebe, K.; Lee, M.J.; Kim, Y.S.; Trepel, J.; L., N. Sensitivity of epidermal growth factor receptor and ErbB2 exon 20 insertion mutants to Hsp90 inhibition. Br. J. Cancer, 2007, 97, 741-744.
53. Mimnaugh, E.G.; Xu, W.; Vos, M.; Yuan, X.; Isaacs, J.S.; Bisht, K.S.; Gius, D.; Neckers, L. Simultaneous inhibition of hsp 90 and the proteasome promotes protein ubiquitination, causes endoplasmic reticulum-derived cytosolic vacuolization, and enhances antitumor activity. Mol. Cancer Ther., 2004, 3, 551-566.
54. Mimnaugh, E.G.; Xu, W.; Vos, M.; Yuan, X.; Neckers, L. Endoplasmic reticulum vacuolization and valosin-containing protein relocalization result from simultaneous hsp90 inhibition by geldanamycin and proteasome inhibition by velcade. Mol. Cancer Res., 2006, 4, 667-681.
55. Mitsiades, C.S.; Mitsiades, N.S.; McMullan, C.J.; Poulaki, V.; Kung, A.L.; Davies, F.E.; Morgan, G.; Akiyama, M.; Shringarpure, R.; Munshi, N.C.; Richardson, P.G.; Hideshima, T.; Chauhan, D.; Gu, X.; Bailey, C.; Joseph, M.; Libermann, T.A.; Rosen, N.S.; Anderson, K.C. Antimyeloma activity of heat shock protein-90 inhibition. Blood, 2006, 107, 1092-1100.
56. Frebel, K.; Wiese, S. Signalling molecules essential for neuronal survival and differentiation. Biochem. Soc. Trans., 2006, 34, 1287-1290.
57. Kefford, R.; Millward, M.; Hersey, P.; Brady, B.; Graham, M.; Johnson, R.G.; Hannah, A.L. Phase II trial of tanespimycin (KOS-953), a heat shock protein-90 (Hsp90) inhibitor in patients with metastatic melanoma [abstract]. J. Clin. Oncol., 2007, 25, 8558.
58. Richardson, P.G.; Chanan-Khan, A.; Lonial, S.; Krishnan, A.; Carroll, M.; Cropp, G.F.; Albitar, M.; Johnson, R.G.; Hannah, A.; Anderson, K. Tanespimycin (T) + bortezomib (BZ) in multiple myeloma (MM): Pharmacology, safety and activity in relapsed/refractory (rel/ref) patients (Pts) [abstract]. J. Clin. Oncol., 2007, 25, 3532.
59. Weigel, B.; Blaney, S.; Kersey, J.; Bagatell, R.; Ivy, S.P.; Whitesell, L.; Krailo, M.; Reid, J.; Ames, M.; Adamson, P. A phase I study of 17-AAG in relapsed/refractory pediatric patients with solid tumors: A Children's Oncology Groups study [abstract]. J. Clin. Oncol., 2006, 24, 9018.
60. Bagatell, R.; Gore, L.; Egorin, M.; Ho, R.; Boucher, N.; Heller, G.; Trippett, T. Phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of 17-Allylamino-17-demethoxygeldanamycin (17AAG) in children with solid tumors [abstract]. J. Clin. Oncol., 2006, 24, 9022.
61. Mitsiades, C.; Chanan-Khan, A.; Alsina, M.; Doss, D.; Landrigan, B.; Kettner, D.; Albitar, M.; Cropp, G.F.; Hannah, A.L.; Richardson, P. Phase 1 trial of 17-AAG in patients with relapsed and refractory multiple myeloma (MM) [abstract]. J. Clin. Oncol., 2005, 23, 3056.
62. Erlichman, C.; Toft, D.; Reid, J.; Goetz, M.; Ames, M.; Mandrekar, S.; Ajei, A.; McCollum, A.; Ivy, P. A phase I trial of 17-allylamino-geldanamycin (17AAG) in patients with advanced cancer [abstract]. J. Clin. Oncol., 2004, 22, 3030.
63. Ramanathan, R.K.; Trump, D.L.; Eiseman, J.L.; Belani, C.P.; Agarwala, S.S.; Zuhowski, E.G.; Lan, J.; Ivy, P.; Tutchko, S.; Egorin, M.E. A phase I pharmacokinetic (PK) and pharmacodynamic (PD) trial of weekly 17-allylamino-17 demethoxygeldanamycin (17AAG, NSC-704057) in patients with advanced tumors [abstract]. J. Clin. Oncol., 2004, 22, 3031.
64. Vaishampayan, U.N.; Sausville, E.A.; Horiba, M.N.; Quinn, M.; Heilbrun, L.K.; Burger, A.; Ivy, P.; Li, J.; Lorusso, P. Phase I trial of intravenous 17-allylaminogeldanamycin (A) and oral sorafenib (B) in pretreated advanced malignancy: Plasma Hsp90{alpha} induction correlates with clinical benefit [abstract]. J. Clin. Oncol., 2007, 25, 3531.
65. Tse, A.N.; Carvajal, R.; Shah, M.; Dials, H.; Fogel, M.; O'Reilly, E.; Chung, K.; Maki, R.; Wu, N.; Egorin, M.; Schwartz, G.K. Phase 1 dose-escalation study of 17-allylamino-17-demethoxygeldanamycin (17AAG) in combination with irinotecan in patients with solid tumors [abstract]. J. Clin. Oncol., 2007, 25, 3533.
66. Chanan-Khan, A.; Richardson, P.; Alsina, M.; Lonial, S.; Krishnan, A.; Carroll, M.; Albitar, M.; Hannah, A.L.; Johnson, R.G.; Anderson, K. Phase 1 clinical trial of KOS-953 + bortezomib (BZ) in relapsed refractory multiple myeloma (MM) [abstract]. J. Clin. Oncol., 2006, 24, 3066.
67. Modi, S.; Stopeck, A.; Gordon, M.S.; Solit, D.; Ma, W.; Wheler, J.; Cropp, G.F.; Johnson, R.G.; Hannah, A.; Hudis, C. Phase I trial of KOS-953, a heat shock protein 90 inhibitor, and trastuzumab (T) [abstract]. J. Clin. Oncol., 2006, 24, 501.
68. Solit, D.B.; Egorin, M.; Kopil, C.; Delacruz, A.; Shaffer, D.; Slovin, S.; Morris, M.; Kelly, W.K.; Rosen, N.; Scher, H. Phase I pharmacokinetic and pharmacodynamic trial of docetaxel and 17AAG (17-allylamino-17- demethoxygeldanamycin) [abstract]. J. Clin. Oncol., 2005, 23, 3051.
69. Solit, D.B.; Egorin, M.; Valentin, G.; Delacruz, A.; Ye, Q.; Schwartz, L.; Larson, S.; Rosen, N.; Scher, H.I. Phase I pharmacokinetic and pharmacodynamic trial of docetaxel and 17AAG (17-allylamino-17- demethoxygeldanamycin) [abstract]. J. Clin. Oncol., 2004, 22, 3032.
70. Haluska, P.; Toft, D.O.; Steinmetz, S.M.; Furth, A.; Mandrekar, S.; Stensgard, B.A.; McCollum, A.K.; Hanson, L.J.; Adjei, A.A.; Erlichman, C. A phase I trial of gemcitabine (Gem), 17-allylaminogeldanamycin (17-AAG) and cisplatin (CDDP) in solid tumor patients [abstract]. J. Clin. Oncol., 2004, 22, 3058.
71. Saif, M.W.; Erlichman, C.; Dragovich, T.; Mendelson, D.; Toft, D.; Timony, G.; Burrows, F.; Padgett, C.; De Jager, R.; Von Hoff, D. Phase I study of CNF1010 (lipid formulation of 17-(allylamino)-17-demethoxygeldanamycin: 17-AAG) in patients with advanced solid tumors [abstract]. J. Clin. Oncol., 2006, 24, 10062.
72. MacRae, C.; Richardson, P.G.; Walker, J.; Grayzel, D.S.; Demetri, G.D. Cardiovascular safety profile of IPI-504 (retaspimycin hydrochloride), a novel Hsp90 inhibitor: Results from two independent phase I trials in patients with advanced cancer [abstract]. J. Clin. Oncol., 2009, 27, e14539.
73. Sequist, L.V.; Janne, P.A.; Walker, J.; Sweeney, J.; Grayzel, D.; Lynch, T.J. Phase I/II trials of the novel Hsp90 inhibitor, IPI-504, in patients with relapsed and/or regractory stage IIIB or stage IV non-small cell lung cancer stratified by EGFR mutation status [abstract]. AACR-NCI-EORTC Int. Conf., 2007, B79.
74. Pacey, S.C.; Wilson, R.; Walton, M.; Eatock, M.; Zetterlund, A.; Arkenau, H.; Beecham, R.; Raynaud, F.; Workman, P.; Judson, I. A phase I trial of the HSP90 inhibitor, alvespimycin (17-DMAG) administered weekly, intravenously, to patients with advanced, solid tumours. J. Clin. Oncol., 2009, 27, 3534.
75. Flaherty, K.T.; Gore, L.; Avadhani, A.N.; Spratlin, J.L.; Harlacker, K.; Zhong, Z.; Johnson, R.G.; Hannah, A.L.; O'Dwyer, P.J.; Eckhardt, S.G. First use of an oral Hsp90 inhibitor in patients (Pts) with solid tumors: Alvespimycin (A) administered QOD or Q [abstract]. J. Clin. Oncol., 2008, 26, 2502.
76. Pacey, S.C.; Wilson, R.; Walton, M.; Eatock, M.; Moreno-Farre, J.; Gallerani, E.; Davergne, V.; Raynaud, F.; Workman, P.; Judson, I. A phase I trial of the heat shock protein 90 (HSP90) inhibitor 17-dimethylaminoethylamino- 17-demethoxygeldanamycin (17-DMAG, alvespimycin) administered weekly [abstract]. J. Clin. Oncol., 2007, 25, 3568.
77. Flaherty, K.T.; Gore, L.; Avadhani, A.; Leong, S.; Harlacker, K.; Zhong, Z.; Johnson, R.G.; Hannah, A.L.; O'Dwyer, P.; Eckhardt, S.G. Phase. 1,. pharmacokinetic (PK) and pharmacodynamic (PD) study of oral alvespimycin (A; KOS-1022; 17-DMAG): Two different schedules in patients with advanced malignancies [abstract]. J. Clin. Oncol., 2007, 25, 14059.
78. Murgo, A.J.; Kummar, S.; Gardner, E.R.; Figg, W.; Chen, X.; Yancey, M.; Ivy, P.; Conley, B.; Doroshow, J.H.; Gutierrez, M.E. Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) administered twice weekly [abstract]. J. Clin. Oncol., 2007, 25, 3566.
79. Lancet, J.; Gojo, I.; Baer, M.; Burton, M.; Klein, M.; Nowadly, C.; Gorre, M.; Zhong, Z.; Johnson, R.G.; Hannah, A.L. Phase. 1,. pharmacokinetic (PK) and pharmacodynamic (PD) study of of the Hsp-90 inhibitor, KOS-1022 (17-DMAG), in patients with refractory hematological malignancies [abstract]. J. Clin. Oncol., 2006, 24, 2081.
80. Egorin, M.J.; Belani, C.P.; Remick, S.C.; Erlichman, C.; Teneyck, C.J.; Holleran, J.L.; Ivy, S.P.; Ramalingam, S.; Naret, C.L.; Ramanathan, R.K. Phase I, pharmacokinetic (PK), & pharmacodynamic (PD) study of 17-dimethylaminoethylamino-17-demethoxygeldanamycin, (17DMAG, NSC 707545) in patients with advanced solid tumors [abstract]. J. Clin. Oncol., 2006, 24, 3021.
81. Miller, K.; Rosen, L.S.; Modi, S.; Schneider, B.; Roy, J.; Chap, L.; Paulsen, M.; Kersey, K.; Hannah, A.; Hudis, C. Phase I trial of alvespimycin (KOS-1022; 17-DMAG) and trastuzumab (T) [abstract]. J. Clin. Oncol., 2007, 25, 1115.
82. Rugo, H.S.; Herbst, R.S.; Liu, G.; Park, J.W.; Kies, M.S.; Pithavala, Y.K.; McShane, T.M.; Steinfeldt, H.M.; Reich, S.D.; Wilding, G. Clinical and dynamic imaging results of the first phase I study of AG-013736, an oral anti-angiogenesis agent, in patients (pts) with advanced solid tumors [abstract]. J. Clin. Oncol., 2008, 26, 2503.
83. Bryson, J.C.; Infante, J.R.; Ramanathan, R.K.; Jones, S.F.; Von Hoff, D.D.; Burris, H. A.,III. A Phase I dose-escalation study of the safety and pharmacokinetics (PK) of the oral Hsp90 inhibitor SNX-5422 [abstract]. J. Clin. Oncol., 2008, 26, 14613.
84. Cavenagh, J.D.; Yong, K.; Byrne, J.; Cavet, J.; Johnson, P.; Morgan, G.; Williams, C.; Akinaga, S.; Francis, G.; Kilborn, J. The Safety, Pharmacokinetics and Pharmacodynamics of KW-2478, a Novel Hsp90 Antagonist, in Patients with B-Cell Malignancies: A First-in-Man, Phase I, Multicentre, Open-Label, Dose Escalation Study [abstract]. ASH Annu. Meet. Abstr., 2008, 112, 2777.
85. Sessa, C.; Sharma, S.K.; Britten, C.D.; Vogelzang, N.J.; Bhalla, K.N.; Mita, M.M.; Pluard, T.J.; Stiegler, P.; Quadt, C.; Shapiro, G.I. A phase I dose escalation study of AUY922, a novel HSP90 inhibitor, in patients with advanced solid malignancies [abstract]. J. Clin. Oncol., 2009, 27, 3532.
86. Ide, S.; Motwani, M.; Jensen, M.R.; Wang, J.; Huseinovic, N.; Stiegler, P.; Wang, X.; Quadt, C. Pharmacodynamics and pharmacokinetics of AUY922 in a phase I study of solid tumor patients [abstract]. J. Clin. Oncol., 2009, 27, 3533.